HER2/NEU negative
Showing 1 - 25 of >10,000
Breast Cancer Trial in Detroit (biological, drug, other)
Terminated
- Breast Cancer
- HER2Bi-armed activated T cells
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Nov 29, 2022
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago
Not yet recruiting
- Estrogen-receptor-positive Breast Cancer
- +3 more
- elacestrant, palbociclib, abemaciclib, ribociclib
-
Chicago, IllinoisNorthwestern University
Sep 25, 2023
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)
Active, not recruiting
- Advanced Breast Cancer
- +2 more
- Talazoparib Tosylate
-
Stanford, CaliforniaStanford University Hospitals and Clinics
Nov 16, 2022
Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Oak Lawn, Houston (Best Practice, Ixabepilone)
Active, not recruiting
- Bilateral Breast Carcinoma
- +2 more
- Best Practice
- Ixabepilone
-
Oak Lawn, Illinois
- +2 more
Mar 10, 2022
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Houston (Radiation Therapy, Therapeutic
Active, not recruiting
- Estrogen Receptor Positive
- +3 more
- Radiation Therapy
- Therapeutic Conventional Surgery
-
Houston, TexasM D Anderson Cancer Center
Jun 14, 2022
Edema, Erythema, Estrogen Receptor Negative Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)
Active, not recruiting
- Edema
- +8 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Jan 23, 2023
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative Trial in Duarte, Rancho Cucamonga, South Pasadena
Completed
- Estrogen Receptor Negative
- +4 more
- everolimus
- +3 more
-
Duarte, California
- +2 more
Jun 6, 2022
Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative Trial in Buffalo (procedure, drug, biological)
Active, not recruiting
- Triple -Negative Breast Cancer
- +4 more
- Biopsy
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Aug 1, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +13 more
- Anastrozole
- +9 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 6, 2023
BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston, Seattle (Educational Intervention, Genetic
Recruiting
- BARD1 Gene Mutation
- +14 more
- Educational Intervention
- +3 more
-
Houston, Texas
- +1 more
Jun 14, 2022
Breast Cancer Trial in Omaha (Palbociclib 125mg)
Recruiting
- Breast Cancer
- Palbociclib 125mg
-
Omaha, NebraskaNebraska Medicine
Mar 3, 2022
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)
Terminated
- Estrogen Receptor Positive
- +16 more
- Biopsy of Breast
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,
Active, not recruiting
- Estrogen Receptor Negative
- +15 more
- Cyclophosphamide
- +6 more
-
Bellevue, Nebraska
- +3 more
Nov 30, 2022
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Active, not recruiting
- Anatomic Stage IIB Breast Cancer AJCC v8
- +19 more
-
Gilbert, Arizona
- +4 more
Dec 6, 2022
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8
Active, not recruiting
- Anatomic Stage II Breast Cancer AJCC v8
- +16 more
- Durvalumab
- Tremelimumab
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)
Active, not recruiting
- Androgen Receptor Positive
- +5 more
- Enobosarm
- +2 more
-
Corona, California
- +6 more
Jun 8, 2022
HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes Trial in Seattle, Madison (Laboratory Biomarker
Active, not recruiting
- HER2/Neu Negative
- +10 more
- Laboratory Biomarker Analysis
- +2 more
-
Seattle, Washington
- +1 more
Jan 11, 2022
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston
Recruiting
- Advanced Breast Carcinoma
- +17 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial in
Active, not recruiting
- Anatomic Stage 0 Breast Cancer AJCC v8
- +21 more
- Ipilimumab
- +2 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022
Collecting, Analyzing, and Storing Samples From Metastatic,
Terminated
- Estrogen Receptor Negative
- +4 more
- Cytology Specimen Collection Procedure
- +3 more
-
Seattle, Washington
- +1 more
Sep 23, 2021
Adult Solid Tumor, Bladder Carcinoma, Colon Carcinoma Trial in Duarte (Laboratory Biomarker Analysis, Modified Vaccinia Virus
Active, not recruiting
- Adult Solid Neoplasm
- +16 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative Trial in United States (procedure, other,
Active, not recruiting
- Estrogen Receptor Negative
- +3 more
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- +3 more
-
Houston, Texas
- +5 more
Feb 11, 2022
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,
Active, not recruiting
- Estrogen Receptor Negative
- +6 more
- Biomarker Analysis
- +3 more
-
Birmingham, Alabama
- +8 more
Feb 3, 2022
Lymphocytes NK Development and Functions forMetastatic Breast
Completed
- Breast Cancer
- prospective study
-
Lyon, France
- +1 more
Feb 3, 2021